PMID- 20652627
OWN - NLM
STAT- MEDLINE
DCOM- 20110707
LR  - 20211020
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 24
IP  - 5-6
DP  - 2010 Dec
TI  - Effect of dronedarone on exercise capacity and cardiac function in patients with 
      severe left ventricular dysfunction and compensated stable heart failure.
PG  - 449-58
LID - 10.1007/s10557-010-6251-y [doi]
AB  - PURPOSE: Dronedarone is a novel multichannel blocker with antiadrenergic and 
      vasodilatory properties. The aim of this study was to investigate the effects of 
      dronedarone on functional capacity in patients with severe left ventricular (LV) 
      dysfunction and compensated stable heart failure (HF). METHODS: This was a 
      multicentre, double-blind, randomized, placebo-controlled, dose-escalating study. 
      Patients in sinus rhythm with impaired LV function (LV ejection fraction 
      [LVEF] </= 30%) and compensated HF (New York Heart Association [NYHA] class I-II), 
      who would continue to receive cardiovascular treatment (excluding antiarrhythmic 
      agents), were eligible. A total of 124 patients were randomized to receive 
      dronedarone (400 mg or 800 mg once daily or 600 mg twice daily) or placebo for 
      30 days. The primary objective was assessment of the effects of dronedarone on 
      functional capacity, using the 6 min walk test. Secondary objectives included the 
      effects of dronedarone on LVEF, cardiothoracic ratio, NYHA status, and Holter 
      parameters. RESULTS: A total of 111 patients completed the study. There were no 
      significant differences between dronedarone and placebo with respect to walking 
      distance and LVEF. The cardiothoracic ratio was similar in all treatment groups 
      throughout the study, and the NYHA status did not change in the majority of 
      patients. Dronedarone was well tolerated and, as expected, decreased heart rate. 
      No new arrhythmic events or torsades de pointes were reported. CONCLUSIONS: 
      Short-term treatment with dronedarone did not affect exercise capacity and did 
      not decrease LVEF in patients with severe LV dysfunction and compensated HF.
FAU - Levine, T Barry
AU  - Levine TB
AD  - Michigan Institute for Heart Failure and Transplant Care, Farmington Hills, MI, 
      USA. tblevine6000@yahoo.com
FAU - Giles, Thomas
AU  - Giles T
FAU - Radzik, David
AU  - Radzik D
FAU - Ghali, Jalal K
AU  - Ghali JK
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Placebos)
RN  - 0 (Vasodilator Agents)
RN  - JQZ1L091Y2 (Dronedarone)
RN  - N3RQ532IUT (Amiodarone)
SB  - IM
MH  - Amiodarone/adverse effects/*analogs & derivatives/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Dronedarone
MH  - Exercise/physiology
MH  - Exercise Test
MH  - Exercise Tolerance/*drug effects
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Vasodilator Agents/adverse effects/therapeutic use
MH  - Ventricular Dysfunction, Left/*drug therapy/physiopathology
MH  - Ventricular Function, Left/*drug effects
PMC - PMC3051062
EDAT- 2010/07/24 06:00
MHDA- 2011/07/08 06:00
PMCR- 2011/01/13
CRDT- 2010/07/24 06:00
PHST- 2010/07/24 06:00 [entrez]
PHST- 2010/07/24 06:00 [pubmed]
PHST- 2011/07/08 06:00 [medline]
PHST- 2011/01/13 00:00 [pmc-release]
AID - 6251 [pii]
AID - 10.1007/s10557-010-6251-y [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2010 Dec;24(5-6):449-58. doi: 10.1007/s10557-010-6251-y.